Mode
Text Size
Log in / Sign up
N/A N=65 Randomized Triple-blind Treatment

A Novel fNIRS Neurofeedback Intervention for Enhancement of Working Memory in Attention Deficit Hyperactivity Disorder (ADHD)

ADHD

Enrolled (actual)
65
Serious AEs
0.0%
Results posted
Dec 2023
Primary outcome: Primary: Change in Target Frontal-parietal Activity — 2.31; -4.74 beta coefficient

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Neurofeedback (Behavioral); Cognitive training (Behavioral)
Age
Pediatric · 7+ yrs
Sex
All
Sponsor
Stanford University
Primary completion
Aug 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Target Frontal-parietal Activity
2.31; -4.74
PRIMARY
Change in Working Memory Performance
2.12; -0.53
SECONDARY
Change in Behavior Rating Inventory of Executive Function (BRIEF), Working Memory T-score
-8.4; -0.85
SECONDARY
Change in Wide Range Assessment of Memory and Learning 2 (WRAML-2), General Memory Index Score
6.6; 9.38
SECONDARY
Change in Conners 3rd Edition ADHD Index Score
-6.21; -1
SECONDARY
Change in Conners 3rd Edition Inattention T-score
-4.8; 0.41
SECONDARY
Change in Developmental NEuroPSYchological Assessment II (NEPSY-II) Composite Score
0.72; 1.05

Summary

The proposed study is to test and validate a novel intervention that integrates computerized cognitive training with real-time neuromonitoring and neurofeedback to enhance working memory by probing the individualized neural systems underlying working memory. We will test the proposed intervention on children with ADHD with working memory deficits. The R61 proof-of-concept phase will assess the target engagement, effective dose and feasibility.

Eligibility Criteria

Inclusion criteria include:

  • Age from 7 to 11 years
  • Diagnosis and/or current symptoms of ADHD
  • Full-scale Intelligence quotient (IQ) ≥80
  • Behavior Rating Inventory of Executive Functions (BRIEF), Working Memory Scale t-score > 65
  • Allowed comorbidities include oppositional defiant disorder, learning disabilities excluding dyslexia, and mild anxiety and/or depression.

Exclusion criteria

  • Presence of severe neurological or psychiatric disease other than those allowed under inclusion
  • Sensory deficits that would preclude participation in assessments or imaging
  • History of significant head trauma with loss of consciousness
  • Contraindications to MRI (e.g. metal implants or claustrophobia)
  • Enrollment in other intervention studies
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04002167). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search